Good
Mostly Aligned
Patient Risk:
Low
Summary
Most interaction- and safety-related claims align with the provided Lipitor label (notably myopathy/rhabdomyolysis risk with strong CYP3A4 inhibitors and grapefruit, plus liver monitoring). However, several claims are only partially supported because the label does not explicitly state the same wording/mechanism, and at least one symptom claim (dark/tea-colored urine) is not supported by the provided label text.
Category Scores
Accurate Statements
Lipitor interactions (with certain drugs) can increase risk of serious muscle injury (myopathy/rhabdomyolysis).
Supported by 5.1 Skeletal Muscle and 7 Drug Interactions.
Strong inhibitors of CYP3A4 can increase atorvastatin plasma concentrations and increase muscle risk.
Supported by 7.1 Strong Inhibitors of CYP 3A4 and 5.1 Skeletal Muscle.
Using lower Lipitor doses can be considered when taken with drugs that increase myopathy risk.
Supported by 5.1 Skeletal Muscle and specific dose cautions/recommendations in 2.6.
Clinicians may consider monitoring for muscle symptoms and may consider periodic CPK determinations in certain interacting-drug situations.
Supported by 5.1 Skeletal Muscle.
Lipitor can affect liver enzymes; statins are associated with biochemical abnormalities of liver function.
Supported by 5.2 Liver Dysfunction and 6 Adverse Reactions (liver enzyme abnormalities referenced).
Patients should be advised to report unexplained muscle pain, tenderness, or weakness; myopathy risk is increased with certain interacting medications or larger grapefruit juice quantities.
Supported by 5.1 Skeletal Muscle and 17.1 Muscle Pain.
Unsupported Statements
Dark or tea-colored urine can be a sign of serious muscle injury, particularly when Lipitor is paired with an interacting medication.
Not found in the provided label excerpts (5.1 Skeletal Muscle / 17.1 Muscle Pain) for the symptom description.
Contradictions
Important Omissions
The label does not support broad guidance that 'many clinicians recommend avoiding grapefruit ... especially at higher doses'; the label instead provides a specific warning/threshold for excessive grapefruit juice (>1.2 liters/day) and notes increased risk with larger quantities.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims reflect on-label warnings regarding myopathy risk with strong CYP3A4 inhibitors and grapefruit exposure, and on-label liver monitoring/caution. One unsupported symptom claim (dark/tea-colored urine) could mislead symptom recognition beyond what is supported by the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One specific symptom claim (dark/tea-colored urine) is not supported by the provided label excerpts; several other claims are only partially supported due to imprecise wording (mechanism/clinical-behavior generalizations).
Suggested Improvement
Remove or revise the unsupported urine-color symptom claim. Align grapefruit guidance to the label’s specific threshold/wording (excessive grapefruit juice >1.2 L/day) and avoid attributing non-labeled general statements (e.g., 'many clinicians recommend') unless explicitly supported by the label text provided.